Haacke H, Parwaresch M R, Mäder C
Atherosclerosis. 1980 Sep;37(1):77-85. doi: 10.1016/0021-9150(80)90095-7.
The effect of 50 mg/kg body weight Xantinol-nicotinate (XN) on serum lipids and on non-esterified fatty acids (NEFA) was tested in 94 out-patients with hyperlipoproteinemia Types IIa, IIb, IV and V. The lipids were measured before treatment, during a 3-week period of drug administration and 10 days after rejection. In each group of hyperlipoproteinemic patients the lipid lowering effect of XN was accompanied by a constant fall in serum NEFA levels. The time dependent course of NEFA showed that the higher the initial level, the longer the time span required to achieve the lowest values. In the context of the partially conflicting data on the hypolipidemic action of nicotinic acid and its derivatives, it is suggested that the constant decrease in NEFA induced by XN treatment might contribute significantly to the lipid lowering effect of this drug.
对94例IIa型、IIb型、IV型和V型高脂蛋白血症门诊患者测试了50毫克/千克体重的烟醇酯（XN）对血脂和非酯化脂肪酸（NEFA）的影响。在治疗前、给药3周期间以及停药10天后测量血脂。在每组高脂蛋白血症患者中，XN的降脂作用伴随着血清NEFA水平持续下降。NEFA的时间依赖性过程表明，初始水平越高，达到最低值所需的时间跨度越长。鉴于关于烟酸及其衍生物降血脂作用的部分相互矛盾的数据，提示XN治疗引起的NEFA持续下降可能对该药物的降脂作用有显著贡献。
